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Abstract: 177Lu-PSMA-617 was prepared at the optimized conditions (95°C, 15-18 µg peptide, 35-40 min; solid phase 
purification) using 177Lu obtained from 176Lu(n, γ)177Lu reaction(>98%, ITLC, HPLC, S.A. 22-24 TBq/mM) followed by 
stability (up to 48 h), biodistribution studies (up to 168 h), planar imaging, compartmental modeling and dosimetry 
estimations via Sparks’s extrapolation method in human organs. Kidney is the critical organ with the dose of 0.067 
mGy/MBq and the radiopharmaceutical can be safely used in trials considering the human dose. 
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INTRODUCTION 
Prostate cancer (PC) known as the second most 
popular cancer in men [1], can be treated if detected in 
the early stages. While the prostate specific membrane 
antigen (PSMA) expression increased significantly in 
prostate cancer tissue [2], it has been characterized as 
a viable and useful biomarker over the twenty years 
from its discovery and many radiolabeeled compounds 
of PSMA have been developed for the diagnosis and 
therapy of PCs [3, 4]. 
PSMA-HBED-CC labelled with 68Ga represents a 
successful novel PSMA inhibitor radiotracer and has 
recently demonstrated its suitability in individual first-in-
man studies [5], the HBED-CC chelator (N,N′-bis[2-
hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N′-
diacetic acid)is not suitable for radiolabeling with 
therapeutic radiometals [6]. Beside the slightly modified 
chemical structure of the molecules synthesized for 
binding to PSMA, these molecules differ mainly in the 
selection of the chelator for the complexation of the 
desired radionuclide [7-9].  
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid, known as DOTA, and its analogues are the 
mostly used chelator for the complexation of 
radiometals specially to small molecules [10, 11] and 
form stable complexes with a broad range of 
radiometals especially with 90Y and 177Lu. 
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Recently, 2-[3-(1-Carboxy-5-{3-naphthalen-2-yl-2-
[(4-{[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-
cyclododec-1-yl)-acetylamino]-methyl}-
cyclohexanecarbonyl)-amino]-propionylamino}-pentyl)-
ureido]-pentanedioic acid (PSMA-617) has been 
introduced as the DOTA-based synthesized PSMA 
(Figure 1) [12]. 131I-labeled PSMA ligand (131I-MIP-
1095) indicated promising results as a new tumour 
targeting agent [13]. However, some limitations of 131I 
such as high radiation burden and even hampering in 
most countries make 177Lu as a better candidate than 
131I. 177Lu with favourable physical characteristics 
[t1/2=6.73 d, Eβmax = 497 MeV, Eγ=112 keV (6.4%), 208 
keV (11%)], has been identified as one of the most 
promising radionuclides for the therapeutic applications 
[14].  
 
Figure 1: Chemical structure of PSMA-617. 
177Lu labeled PSMA-617 has newly been 
introduced, showing high potential in the clinical 
management of advanced PCs in its first human study 
[15]. Despite of the excellent characteristics of 177Lu-
PSMA-617 as the novel theranostic drug in the 
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treatment of the advanced PC, there is no adequate 
published data in preclinical aspects of this 
radiopharmaceutical and therefore more preclinical 
data on its biodistribution and its absorbed dose in 
different organs is required for its performance 
evaluation. 
Absorbed dose is an important parameter in 
evaluating the hazards regarding the administration of 
radiopharmaceuticals and so the maximum amount of 
activity that should be assumed. This concern is 
naturally increased in therapeutic approach where a 
significant absorbed dose may be received by other 
organs and in particular by radiosensitive organs [16]. 
At the present time, in nuclear medicine, the radiation 
absorbed dose assessment resource (RADAR) is 
identified as the mostly used method for the internal 
dose calculation [17]. 
Evaluation of the radiation absorbed dose from 
biodistribution data in animals is a necessary 
requirement for the clinical use of a new 
radiopharmaceutical [18]. Several approaches have 
been previously offered to estimate the human organs 
uptakes using the animal data including dose by factor, 
similar drug, pharmacokinetic ally guided, and 
comparative approaches and also the methods 
presented by Sparks et al. [19, 20]. Sparks et al. 
hasexplained four extrapolation methodestothis action 
[21]: 1. no extrapolation, 2. relative organmass extra- 
polation, 3. physiological time scaling 4. mass and time 
scalings.  
Compartmental modeling, as the most commonly 
used method for describing the uptake, metabolism 
and elimination of radioactive tracers in tissue [22-24], 
can specify that all molecules of tracer delivered to the 
system (i.e., injected) will at any given time exist in one 
of many compartments [25]. The most common use of 
compartmental modeling is the mathematical 
description of the distribution of a radiolabeled complex 
throughout the body [22, 26]. The compartmental 
model also describes all of the possible transformations 
that can occur to the complex, permitting it to shift from 
one compartment to the other compartment and so on. 
So, the fractional rate of this change of the complex 
concentration in one compartment is called a rate 
constant, generally identified as “k” with units of inverse 
time [25]. Therefore, the biological modeling by 
Compartmental analysis can solve the abovementioned 
requirements restrictions in extrapolation methods. 
In this research work, the authors attempted to 
introduce the supplementary preclinical data of 177Lu-
PSMA-617 and related aspects of its production. The 
optimized conditions for the preparation of this new 
therapeutic complex was investigated while the 
radiochemical purity was assessed using both of HPLC 
and ITLC procedures. Also, with the aim of assessing 
the uptake of the complex in normal tissues, the 
biodistribution of the radiolabeled agent was 
investigated in healthy rats at specified time intervals 
after injection by sacrifice and SPECT imaging. Finally, 
dosimetry estimations in human organs were 
performed via relative organ mass extrapolation 
method using biodistribution Compartmental modeling 
data. The obtained human absorbed dose were 
comparable with the human dosimetry data reported in 
the other literature. 
EXPERIMENTAL 
177Lu was produced by neutron bombardment of 
176Lu via 176Lu (n,γ)177Lu nuclear reaction. Enriched 
Lu2O3 (176Lu, 52%)was obtained from ISOTEC Inc. 
PSMA-617 was supplied from ABX (Radeberg, 
Germany). All of the other chemical reagents and 
Whatman No. 2 paper were purchased from Sigma-
Aldrich Chemical Co and (Heidelberg, Germany). 
Whatman (Buckinghamshire, U.K.), respectively. 
Radio-chromatography of the papers was performed by 
a thin layer chromatography scanner (Bioscan AR2000, 
Paris, France). The activity of the samples was 
measured by a p-type coaxial high purity germanium 
(HPGe) detector (model: EGPC 80-200R) coupled with 
a multichannel analyzer system (GC1020-7500SL, 
Canberra, U.S.A.). Reverse phase high performance 
liquid chromatography (RP-HPLC) was performed for 
radiolabeling and specific activity analyzed of the final 
product using a KNAUER-D-14163 system, Berlin, 
Germany. Planar images were captured by a dual head 
SPECT system (DST-XL, SMV, Buc, France). All 
values were expressed as mean ± standard deviation 
(Mean ± SD) and the data were compared using 
Student's T-test. Statistical significance was defined as 
P<0.05. The United Kingdom Biological Council's 
Guidelines on the Use of Living Animals in Scientific 
Investigations, second edition was considered as the 
basis of animal studies. 
Production and Quality Control of 177LuCl3 Solution 
100 µg of enriched Lu2O3 (176Lu, 52% from ISOTEC 
Inc.) was irradiated in a research reactor at a thermal 
neutron flux of 5 × 1013 n.cm–2·s–1 for 5 d. Then, the 
irradiated target was dissolved in 200 µL of 1.0 M HCl 
and diluted to the appropriate volume with ultra pure 
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water, according to the method described in the 
previous related studies [27]. Beta spectroscopy as 
well as HPGe spectroscopy was utilized for the 
assessment of radionuclidic purity. Instant thin layer 
chromatography method (ITLC) was used for checking 
the radiochemical purity, while, 10 mM DTPA (pH = 4) 
and ammonium acetate 10%: methanol (1:1) were 
considered as the solvent systems.  
Radiolabelling of PSMA-617 with 177LuCl3 
As proposed in previous investigation by authers 
[12], a stock solution of PSMA-617 in the distilled water 
was added to the vial containing 177LuCl3, while, 
several experiments were performed for the 
determination of the optimized conditions. Ultimately, 
the final solution was passed through a C18 Sep-Pak 
column preconditioned with 5 mL ethanol, 10 mL water 
and 10 mL air, respectively. The column was then 
washed with 1 mL ethanol and 9 mL of 0.9% NaCl.  
Both HPLC and ITLC methods were applied for the 
radiochemical purity assessment. HPLC was carried 
out by means of MZ-Analysentechnik, ODS-H 5µm 
(100×4.0 mm) column. The following mobile phases 
were employed: A= Ultra pure water-TFA 1% (V/V); 
B=Acetonitrile HPLC Grade using gradient-elution: 0-3 
min, A:100%, B: 0%; 3-10 min, A:50%, B: 50%; 10-15 
min, A:0%, B:100%; Flow rate:1.5 mL/min, Injection 
volume: 20 µL. In the case of ITLC, 0.9 % NaCl and 0.1 
M sodium citrate were selected as the mobile phases. 
STABILITY TESTS 
This step of the current study was performed in 
accordance with some of the previous same works 
[28]. A given amount of complex (approximately, 200 
µCi) was kept at room temperature for 48 h while being 
checked by ITLC at specified time intervals (2, 4, 24, 
48 and 72 h). Also, for serum stability test, 200 µCi of 
177Lu-PSMA-617was subjoined to 300 µL 
offreshlyhuman serum and then the mixture was 
incubated at 37°C for 48 h, where as its radiochemical 
purity was analyzed by ITLC method at 2,4, 24, 48 and 
72 h after preparation. 
Biodistribution of the Radiolabelled Complex in 
Rats 
The final radiolabelled complex was injected 
intravenously into the rats (100 µL, 5.55 MBq). The 
animals were sacrificed at given times after injection (2, 
4, 24, 48, 72 and 168 h) using the animal care 
protocols. Blood samples were quickly taken from the 
rats. The weight and activity of each tissue was 
measured using a calibrated blance and a p-type 
coaxial HPGe detector coupled with a multi-channel 
analyser and according to the relationships used to 
calculation of the activity concentration [29]. Five rats 
were sacrificed for each interval. Finally, the 
percentage of injected dose per gram (%ID/g) for 
different organs was computed according to the 
previous literatures [30].  
HUMAN ABSORBED DOSE ASSESSMENT 
Calculation of Accumulated Activity Using 
Compartmental Modeling  
Calculation of accumulated activity is the first step in 
human absorbed dose assessment. The accumulated 
source activity for each animal organ was calculated 
via plot of the non-decay corrected %ID/g- time curve 
and according to Equation 1: 
 
!A = A t( ) dt
t1
!
"            (1) 
where A(t) is the activity of each organ at time t. 
Cumulative activity in organs of interest can be 
determined by numeric or compartmental models [31]. 
In fact, the accumulated activity for each source organ 
was calculated by substituting the formulas obtained 
from the compartmental modeling in Equation 3. 
Compartmental analysis support the radiopharma- 
ceuticals design permitting a mathematical separation 
of tissues and organs to determinate the concentration 
of activity in each fraction of interest and pointing 
toward inconsistency in biodistribution and dosimetry 
studies. Additionally, by compartmental analysis it is 
possible to consider different chemical species and to 
predict metabolites [32]. In this model each 
compartment defines one possible state of the tracer, 
specifically its physical location (for example, 
intravascular space, extracellular space, intracellular 
space, and synapse) and its chemical state (i.e., its 
current metabolic form or its binding state to different 
tissue elements, such as plasma proteins, receptors, 
etc.) [25]. 
Extrapolation of Animal Data to Human Ones 
The next step to estimate the human absorbed dose 
is to extrapolate the animal accumulated activity to 
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human ones. Preclinical animal studies are used to 
develop the new radiopharmaceuticals with the goal of 
determining a preliminary approximation of absorbed 
dose in human organs. In the previous attempts, in 
direction to estimate the absorbed dose of human 
organs using animal data, several extrapolation 
techniques have been applied to compensate the 
differences of metabolism, anatomy and biodistribution 
of radiopharmaceuticals between animals and humans. 
The accumulated activity of human organs was then 
calculated using relative organ mass extrapolation 
(Equ. 4) [19]. 
             (4) 
Equivalent Absorbed Dose Calculation 
Calculation of the absorbed dose in human organs 
was accomplished by means of RADAR formalism as 
described in previous studies [27]: 
 D = !A ! DF            (5) 
where  !A  is the accumulated activity for each human 
organ, and DF expressed in mGy/MBq.s is a factor 
considering the physical decay characteristics of the 
radionuclide, the range of the emitted radiations, and 
the organ size and configuration [33]. In this research, 
DFs have been taken from the amount presented in 
OLINDA/EXM software [34].  
Effective Absorbed Dose Calculation 
The effective absorbed dose for each organ was 
calculated by multiplying the tissue weighting factor 
(WT) and the equivalent absorbed dose (HT) by means 
of the following Equation 
E = WTHT
T
!            (7) 
WT was obtained from the reported value in ICRP 103. 
Imaging Studies 
Planar images were obtained after 24 and 48 hours 
of intravenous administration of the radiolabelled 
complex in the healthy Syrian rats by a dual head 
SPECT system, whereas the mouse-to-high energy 
septa distance and the useful field of view (UFOV) 
were considered equal to 12 cm and 540 mm×400 mm, 
respectively. 
RESULTS AND DISCUSSION 
The specific activity of 90-100 GBq/mg was 
obtained for 177Luin this research. A p-type coaxial 
HPGe detector was used to check the radionuclidic 
purity. Whereas the peaks of 112 and 208 keV related 
to 177Lu were observed, the radionuclidic purity was 
obtained more than 99.9 %. Only a few impurity was 
obtained which related to 177mLu. Radiochemical purity 
of the 177LuCl3 solution was checked using Whatman 
No.2 paper and in solvent systems of 10 mM DTPA 
and 10% ammonium acetate:methanol (1:1). In a 
mixture of 10 mM DTPA solution (pH 5), free 177Lu3+ 
cation is converted to more lipophilic 177Lu-DTPA form 
and migrates to higher Rf (Rf.0.8). In the case of 10% 
ammonium acetate:methanol (1:1), 177Lu3+ remains at 
the origin while other ionic species would migrate to 
higher Rfs. The results indicated the radiochemical 
purity of higher than 98%. 
Changing in different reaction parameters such as 
the ligand concentration, pH, temperature and reaction 
time was used to obtain the maximum complexation 
yields. The effect of pH on complexation yield was 
studied by varying the pH of the reaction mixture using 
HEPES from 3 to 5. The results indicated that the 
optimum pH for radiolabeling is 4-4.5. Also, the effect 
of the ligand amount on the radiochemical yield was 
checked. The results indicated that by adding the 
certain amount of the ligand (15 µg, 14.4 nmol) to the 
vial containing 177LuCl3 (with a maximum activity of 10 
mCi), 177Lu-PSMA-617 can be prepared with the 
complexation yield of higher than 99% and specific 
activity of 22-24 TBq/mM. While the temperature of 90-
95 °C is required, the experiments showed that 35-40 
min is the optimum radiolabeling reaction time. 
Both HPLC and ITLC methods was applied to check 
radiochemical purity of the radiolabelled complex. In 
the case of ITLC method, in both 0.1 M sodium citrate 
and 0.9% NaCl as the mobile phases with Whatman 
No.2 as the stationary phase, the radiolabelled 
compound remains at the origin, while free 177Lu cation 
migrates to higher Rf (Figure 2). 
HPLC analysis showed that the fast eluting 
compoundwas hydrophilic 177Lu cation (1.0 min), while 
177Lu-PSMA-617 with high molecular weight was eluted 
after 4.47 min (Figure 3). Both the HPLC and ITLC 
chromatograms showed the radiochemical purity of 
more than 99%. 
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The stability of the radiolabelled complex was 
investigated in room temperature and in human serum 
at 37 °C. The radiochemical purity of the complex 
remained >98% at room temperature and in freshly 
prepared human serum at 37 °C even after 48 h of 
preparation. 
The biodistribution data of 177Lu-PSMA-617was 
obtained following sacrifice and the activity 
measurement of each tissue and calculated as the 
percentage of area under the curve of the related photo 
peak per gram of tissue (% ID/g). However, in this 
research, the carrier added 177Lu is used in the 
experiments, but it seems that the biodistribution of no 
carrier added and carrier added 177Lu-PSMA be 
identical in accordance to the other previous research 
which indicated the same biodistribution for carrier 
added and no carrier added radiolabeled compound 
[35]. 
The results demonstrated significant uptake in the 
kidneys as the major route of excretion, which is due to 
the physiological PSMA expression in the kidneys [2] 
and is in accordance to the other reported radiolabelled 
complex of PSMA [36]. The maximum uptake in the 
kidney was occurred at 2 h post injection while 
decrease rapidly with time (Figure 4). 
Less than 0.2% of the injected dose per gram was 
observed in blood after 2 h, which shows fast clearance 
from the circulation and is a major advantage since the 
dose to non-target organs reduce significantly. While 
 
Figure 2: ITLC chromatogram of 177LuCl3 (right) and 177Lu-PSMA-617 (left) in 0.9% NaCl using Whatman No.2. 
 
 
Figure 3: HPLC chromatogram of 177Lu-PSMA-617 prepared at optimized conditions. 
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the accumulation of the activity in the spleen and liver 
diminish slightly with time, intestine uptake reaches its 
maximum amount at 24 h post injection.  
Recently, a study has been reported on the 
synthesis of DOTA-conjugated PSMA inhibitor (PSMA-
617) and its radiolabeling with 67/68Ga and 177Lu [3]. 
 
Figure 4: Percentage of injected dose per gram (%ID/g) at 2, 4, 24, 48, 72 and 168 h after intravenously injection of 177Lu-
PSMA-617 (5.55 MBq) into breast adenocarcinoma-bearing BALB/c mice (%ID/g: percentage of injected dose per gram of 
tissue calculated based on the area under curve of 112 keV peak in gamma spectrum) (n=5). 
 
 
Figure 5: The non-decay corrected injected activity curves after 177Lu-PSMA-617 injection to animal models for prostate, 
pancreas, bone, muscle, lungs and kidneys. 
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However, this study has more emphasized on the 
synthesis of this new PSMA analogue, the 
biodistribution of the radiolabelled complexes were also 
investigated in BALB/c nu/nu mice bearing LNCaP 
xenografts but in the limited times after injection. In the 
case of 177Lu-PSMA-617, the biodistribution data only 
was presented after 1 h and 24 h post injection, while 
according to the half-life of 177Lu (6.7 d), more 
preclinical data on healthy rats especially in the longer 
intervals seems to be essential.  
In this study, with regard to the importance of the 
activity distribution through non-target organs which 
lead to the undesirable absorbed dose, 177Lu-PSMA 
was prepared and biodistribution studies were carried 
out in different organs of the Syrian rats at specified 
intervals (2 to 168 h) post injection. Consistent with the 
previously reported literature, significant accumulation 
was observed in the kidneys with a rapid decrease with 
time.  
Also, as mentioned previously, a small %ID/g was 
observed in the lung at 2 h post injection which is in 
great accordance with Benešová et al. Findings [4]. 
Some uptakes of the activity has been observed in the 
salivary gland. Figures 6 and 7 demonstrate the wash 
out of activity from each critical issue during experiment 
time frame. 
The accumulated activity for each animal organ was 
calculated by integration of the formulas obtained from 
 
Figure 6: The non-decay corrected injected activity curves after 177Lu-PSMA-617 injection to animal models for stomach, liver, 
spleen, heart, intestine, and blood. 
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the compartmental modeling. The non decay corrected 
injected activity curves, the related formulas and the 
calculated accumulated activity for each source organ 
have been shown in Tables 1 and 2, respectively. 
Human absorbed dose estimation was carried out 
by RADAR method based on biodistribution data in the 
rat organs. The equivalent and effective absorbed dose 
in human organs after intravenously injection of 177Lu-
PSMA-617 are presented in Table 2. The highest 
absorbed dose for 177Lu-PSMA-617 is observed in the 
kidney with 0.067 mGy/MBq. 
SPECT images were acquired at 2, 24, 72 and 168 
h after 177Lu-PSMA-617 injection in the normal Syrian 
rats (Figure 7). As it can be seen, the only visible 
organs were the kidneys and the bladder.  
CONCLUSION 
In this study, the more detailed preclinical aspects 
of 177Lu-PSMA-617 was presented. The optimized 
condition for the preparation of this agent was obtained 
with 15 µg of PSMA, pH of 4-4.5, temperature of 90-
95°C. The complex was developed with radiochemical 
purity of higher than 99% and specific activity of 23.4 
MBq/nmol in 35-40 min. The biodistribution of the 
177Lu-PSMA-617 complex in different intervals (2-168 
h) in numerous organs after intravenous injection into 
the rats was evaluated. The final results indicated 
significant accumulation in the kidneys with a fast-
temporal decrease. The biodistribution modeling of the 
complex was done for each organ presenting the 
cumulative activity of the organs at each time point 
after injection. The absorbed dose estimation of 177Lu-
PSMA-617 showed the highest amount in the kidney 
with 0.067 mGy/MBq. According to the fast clearance 
of activity from blood circulation and the kidneys, as the 
major route of excretion, and besides insignificant 
activity aggregation in the other organs, this complex 
can be regarded as an ideal radiolabelled complex for 
the therapeutic purposes in the patients suffering PCs. 
 
Figure 7: SPECT images of 177Lu-PSMA-617 following 5.55 MBq injections in BALB/c nude mice bearing adenocarcinoma 
breast tumor after 5 min (a) 30 min (b) 60 min (c). 
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Table 1: The Compartmental Modeling Formulas of Non-Decay Corrected Injected Activity Curves after 177Lu-PSMA-
617 Injection to the Syrian Rats 
Blood F1=1.2*exp(-2.64*x)+0.00357* exp (-0.14*x)+0.0768* exp (-0.06*x)+0.0000594* exp (-0.000099*x) 
Heart F2=0.0785385* exp (-0.38*x)+0.0000774* exp (-0.07*x)+0.0010125* exp (-0.00099*x)+0.000441* exp (-0.001*x)+0.01935* exp (-0.077*x)-0.0000041625* exp (-5.14*x)-0.00000000639* exp (-0.24*x) 
Lung 
F3=0.03* exp (-0.099*x)+0.138736* exp (-0.26*x)+0.0001376* exp (-0.062*x)+0.0024784* exp (-0.001*x)-0.0108* exp (-
0.077*x)+0.0012* exp (-0.0523*x)-0.023941546* exp (-0.42*x)-0.00031412* exp (-0.017*x)-0.023141412* exp (-1.18*x)-
0.0000258* exp (-0.0999*x) 
Stomach F4=0.6686627* exp (-5.04*x)+8.4899* exp (-0.64*x)+0.039061* exp (-0.14*x)+0.24344* exp (-0.006*x)+0.02544* exp (-0.019*x)-0.282* exp (-0.091*x) 
Intestine F5=0.5* exp (-1.38*x)-0.0018* exp (-0.24*x)-0.0028* exp (-0.24*x)+1.44* exp (-0.57*x)+0.022* exp (-0.0099*x)+0.0196* exp (-0.01*x)+0.0016* exp (-0.077*x) 
Liver F6=0.01791342* exp (-0.45*x)+0.0002408* exp (-0.06*x)+0.0565* exp (-0.0399*x)+0.0001372* exp (-0.001*x)+0.0019* exp (-0.087*x)-0.00001295* exp (-5.04*x)-0.0000000588* exp (-0.14*x) 
Spleen F7=0.1* exp (-0.15*x)-0.185* exp (-3.14*x)-0.0784* exp (-0.03*x)+0.144* exp (-0.67*x)+0.033* exp (-0.0099*x)+0.000196* exp (-1*x)+0.045* exp (-0.0007*x) 
Kidney F8=-0.159* exp (-5.04*x)-0.0000147* exp (-1.64*x)+0.00047* exp (-0.14*x)+2.02* exp (-0.06*x)+0.00000809* exp (-0.000099*x) 
Muscle F9=0.04578723* exp (-0.39*x)+0.0015652* exp (-1.79 *x)+0.0034125* exp (-0.0099*x)+0.008918* exp (-0.031*x)+0.004368* exp (-0.0073*x)-0.00084175* exp (-2.484*x)-0.000012922* exp (-1.674*x) 
Pancreas F10=0.3994026* exp (-0.45*x)+0.00268* exp (-0.077*x)+0.00845* exp (-0.00099*x)+0.00004116* exp (-0.001*x)+0.00007224* exp (-0.06*x)-0.00000005964* exp (-0.14*x)-0.00003885* exp (-5.04*x) 
Prostate F12=17.21026* exp (-1.45*x)+0.00378* exp (-0.077*x)+0.00945* exp (-0.00099*x)+0.0004116* exp (-0.001*x)+0.00007224* exp (-0.06*x)-0.00000005964* exp (-0.14*x)-0.00003885* exp (-5.04*x) 
Bone F11=0.9983* exp (-0.057*x)+0.01* exp (-1.2*x)+0.08956* exp (-0.08*x)+0.002254* exp (-0.0000008*x)+0.021275* exp (-0.38*x)+0.05964* exp (-6.14*x)-0.003266* exp (-0.44*x) 
 
Table 2: Equivalent Absorbed dose Delivered into each Human Organ after Injection of 177Lu-PSMA-617 
Target Organ Equivalent Absorbed dose in Humans (mGy/MBq) Target Organ 
Equivalent Absorbed dose in Humans 
(mGy/MBq) 
Adrenals 0.0005 Muscle 0.0034 
Brain 0.0001 Ovaries 0.0003 
Breasts 0.0000 Pancreas 0.0042 
GB Wall 0.0003 Red Marrow 0.0093 
LLI Wall 0.0144 Bone Surf 0.0219 
Small Int 0.0003 Spleen 0.0314 
Stomach Wall 0.0031 Testes 0.0001 
ULI Wall 0.0002 Thymus 0.0002 
Heart Wall 0.0023 Thyroid 0.0002 
Kidneys 0.0671 UB Wall 0.0002 
Liver 0.0031 Total Body 0.0121 
Lungs 0.0016   
GW: Gallbladder Wall; LLI: lower large intestine; Int: Intestine; ULI: upper large intestine; UB Wall: Urinary Bladder Wall.  
a Tissue weighting factors according to international commission on radiological protection, ICRP 103 (2007).  
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